Chemoimmunotherapy for chronic lymphocytic leukemia

Last medical review:

Chemoimmunotherapy combines chemotherapy with monoclonal antibodies. Chemotherapy uses anticancer drugs to destroy cancer cells. Monoclonal antibodies are a type of targeted therapy. They stimulate the body's immune system to attack and destroy chronic lymphocytic leukemia (CLL) cells. Chemoimmunotherapy is a systemic therapy. This means that the drugs travel through the blood to reach and destroy cancer cells all over the body.

If you have chemoimmunotherapy, your healthcare team will use what they know about the cancer and about you and your overall health to plan the drugs, doses and schedules. It is a treatment option if you have CLL that does not have a 17p chromosome deletion or a TP53 gene mutation and the IGHV gene is mutated.

Chemoimmunotherapy is given for a limited time of around 6 months, so you may need other treatment.

Chemoimmunotherapy drugs used for CLL

The most common chemoimmunotherapy combinations used to treat CLL are:

  • FCR – fludarabine (Fludara), cyclophosphamide (Procytox) and rituximab (Rituxan and biosimilars)
  • BR – bendamustine (Treanda, Benvyon, Esamuze) and rituximab
  • chlorambucil (Leukeran) and obinutuzumab (Gazyva)

Side effects of chemoimmunotherapy

Side effects of chemoimmunotherapy will depend mainly on the drug or drug combination, the dose, how it’s given and your overall health. Tell your healthcare team if you have side effects that you think are from chemoimmunotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.

Possible side effects of chemoimmunotherapy drugs for CLL include:

Find out more about treatment

Find out more about chemotherapy and targeted therapy.

Details on specific drugs change regularly. Find out more about sources of drug information and where to get details on specific drugs.

Expert review and references

  • Versha Banerji, MD, FRCPC
  • Guideline Resource Unit. Chronic Lymphocytic Leukemia. Version 8 ed. Edmonton: Alberta Health Services; 2023: https://www.albertahealthservices.ca/.
  • American Cancer Society . Treating Chronic Lymphocytic Leukemia . 2018 : https://www.cancer.org/.
  • Wierda WG, O'Brien SM. Chronic lymphocytic leukemias. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: Kindle version, ch 105, https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • Chronic Lymphocytic Leukemia Clinic. Practice Guideline: Disease Management Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia. Winnipeg, MB: CancerCare Manitoba; 2015.
  • Muhsin Chisti M. Medscape Reference: Chronic Lymphocytic Leukemia (CLL) Treatment and Management. WebMD LLC; 2020: https://www.medscape.com/.
  • PDQ® Adult Treatment Editorial Board. Chronic Lymphocytic Leukemia Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; 2021: https://www.cancer.gov/.
  • National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Version 2.2022) . 2022 .
  • Owen C, Banerji V, Johnson N, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leukemia Research. 2023: 125:107016.
  • Owen C, Eisinga S, Banerji V, et al. Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 2023: 133:107372.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society